title: Delayed adverse reactions to iodinated contrast media and their risk factors.
abstract: OBJECTIVE
  The present prospective survey was performed to obtain information on delayed adverse reactions (DARs) to five types of low-osmolar iodinated contrast media, including their frequency, common manifestations, and the patient's history of allergy.
  
  
  METHODS
  We investigated data from 15,890 consecutive patients who underwent contrast-enhanced computed tomography (CT) during a 15-month period. All patients were given a questionnaire asking about the occurrence of DARs, their symptoms and duration, and asked to consult a dermatologist if they had a skin reaction.
  
  
  RESULTS
  Of 11,121 patients who returned the questionnaire (response rate, 70.0%), DARs were observed in 1,058 patients (9.5%). DARs tended to occur with higher incidence in patients with no previous history of examinations using contrast media, with past adverse reactions caused by contrast media, with a history of allergy, or with a serum creatinine level greater than 2.0 mg/dl. Among the 331 patients who reported skin reactions, 41 patients consulted a dermatologist. Skin reactions were observed significantly more frequently in patients for whom iotrolan was used, and 60% of these reactions were severe or moderate.
  
  
  CONCLUSIONS
  Four risk factors for DARs were identified in the present investigation.
authors.affiliation: Department of Radiology, Yamagata University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Hosoya
authors.forename: K
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: T
authors.initials: T
authors.lastname: Akutsu
authors.forename: Y
authors.initials: Y
authors.lastname: Mitsuhashi
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: Y
authors.initials: Y
authors.lastname: Sugai
authors.forename: M
authors.initials: M
authors.lastname: Adachi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D002648:Child; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D003875:Drug Eruptions / Q000453:epidemiology*; D004342:Drug Hypersensitivity / Q000453:epidemiology*; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology; D015994:Incidence; D007455:Iodine / Q000009:adverse effects*; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000009:adverse effects
chemical_list: D003287:Contrast Media; D014283:Triiodobenzoic Acids; C033300:iotrolan; D007455:Iodine; D003404:Creatinine